Retatrutide (Triple Incretin Pathway Peptide)
Precision Synthesized | Research Grade Compound
Next-generation triple-pathway compound at the forefront of advanced metabolic and weight management research.
Represents the latest evolution in multi-pathway metabolic research, integrating three key signaling systems.
OVERVIEW
Retatrutide is an advanced multi-pathway peptide designed to interact with three key metabolic signaling systems: GLP-1, GIP, and glucagon receptors.
This integrated mechanism has positioned Retatrutide at the forefront of research exploring weight loss pathways, fat metabolism, and energy expenditure. By combining these signaling systems into a single compound, it is studied for its potential to influence appetite regulation, substrate utilization, and overall metabolic efficiency at a broader level than single- or dual-pathway compounds.
Understanding Pathway Progression
Metabolic research compounds are often categorized by how many biological pathways they interact with:
- Single-pathway compounds focus on one primary signaling system
- Dual-pathway compounds expand this interaction across multiple metabolic signals
- Multi-pathway compounds are studied for broader systemic influence
Retatrutide represents the most advanced category, integrating three pathways into a single research model.
Explore Related Compounds
For those researching earlier-stage pathway systems:
- Semaglutide → Foundational single-pathway compound
- Tirzepatide → Dual-pathway metabolic signaling
RESEARCH FOCUS AREAS
Weight Loss & Fat Metabolism Pathways
Studied in relation to mechanisms associated with fat utilization, energy balance, and metabolic efficiency.
Triple-Pathway Metabolic Signaling
Investigated for its combined interaction with GLP-1, GIP, and glucagon receptor systems.
Energy Expenditure Mechanisms
Observed in research exploring pathways linked to increased metabolic output and substrate utilization.
Glucose Regulation & Insulin Response
Preliminary studies indicate involvement in glucose handling and insulin signaling pathways.
RESEARCH APPLICATIONS
- Weight loss and fat metabolism research models
- Multi-pathway metabolic signaling studies
- Energy expenditure and substrate utilization analysis
- Appetite regulation and hormonal signaling research
- Advanced metabolic pathway modelling
SCIENTIFIC REFERENCES
Triple-Hormone-Receptor Agonist Retatrutide for Obesity:
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Retatrutide (LY3437943), a novel GIP, GLP-1, and glucagon receptor agonist:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11486854/
Efficacy and safety of retatrutide in obesity treatment – A Systematic Review:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/
Lilly Triple Agonist Retatrutide Clinical Updates:
https://investor.lilly.com/news-releases/
IMPORTANT NOTICE
This compound is supplied strictly for laboratory research purposes only.
Demure Peptides™ operates as a private sourcing and payment facilitation platform, connecting clients to independent third-party supply channels. All fulfilment, handling, and packaging are conducted externally.
This product is not intended for human consumption.
This product has not been evaluated by the South African Health Products Regulatory Authority and is not intended to diagnose, treat, cure, or prevent any disease.
ADDITIONAL INFORMATION
- Peptide Name: Retatrutide
- Code: LY3437943
- Category: Metabolic Research Peptide
- Format: Vial
- CAS Number: 2381089-83-2
Reviews
There are no reviews yet.